A neutrophil inhibitory pepducin derived from FPR1 expected to target FPR1 signaling hijacks the closely related FPR2 instead

FEBS Letters

Volumn 589, Issue 15, 2015, Pages 1832-1839

  Winther, Malene ^a   Gabl, Michael ^a   Welin, Amanda ^a   Dahlgren, Claes ^a   Forsman, Huamei ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Allosteric modulation; Formyl peptide receptor; G protein coupled receptor; Inflammation; Inhibitor; Pepducin

Indexed keywords

CALCIUM ION; FORMYLPEPTIDE RECEPTOR; FORMYLPEPTIDE RECEPTOR 1; FORMYLPEPTIDE RECEPTOR 2; LIPOPEPTIDE; PEPDUCIN; UNCLASSIFIED DRUG; FPR1 PROTEIN, HUMAN; FPR2 PROTEIN, HUMAN; LIPOXIN RECEPTOR;

ARTICLE; BINDING KINETICS; CYTOSOL; HUMAN; HUMAN CELL; LEUKOCYTE ACTIVATION; LEUKOCYTE FUNCTION; NEUTROPHIL; NEUTROPHIL GRANULE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN TARGETING; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; ADULT; CHEMISTRY; DRUG EFFECTS; HL 60 CELL LINE; METABOLISM;

ADULT; HL-60 CELLS; HUMANS; LIPOPEPTIDES; NEUTROPHILS; RECEPTORS, FORMYL PEPTIDE; RECEPTORS, LIPOXIN; SIGNAL TRANSDUCTION;

EID: 84934443061     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2015.05.050     Document Type: Article

References (35)

1. J.I. Gallin, R. Snyderman, B.F. Haynes, C. Nathan, and D.T. Fearon Inflammation: basic principles and clinical correlates 1999 Lippincott Williams & Wilkins New York
2. E. Kolaczkowska, and P. Kubes Neutrophil recruitment and function in health and inflammation Nat. Rev. Immunol. 13 2013 159 175
3. N. Dufton, and M. Perretti Therapeutic anti-inflammatory potential of formyl-peptide receptor agonists Pharmacol. Ther. 127 2010 175 188
4. H.L. Malech, and J.I. Gallin Current concepts: immunology. Neutrophils in human diseases N. Engl. J. Med. 317 1987 687 694
5. R.D. Ye, F. Boulay, J.M. Wang, C. Dahlgren, C. Gerard, M. Parmentier, C.N. Serhan, and P.M. Murphy International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family Pharmacol. Rev. 61 2009 119 161
6. H. Fu, J. Karlsson, J. Bylund, C. Movitz, A. Karlsson, and C. Dahlgren Ligand recognition and activation of formyl peptide receptors in neutrophils J. Leukoc. Biol. 79 2006 247 256
7. K. O'Callaghan, A. Kuliopulos, and L. Covic Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development J. Biol. Chem. 287 2012 12787 12796
8. J. Miller, A. Agarwal, L.A. Devi, K. Fontanini, J.A. Hamilton, J.P. Pin, D.C. Shields, C.A. Spek, T.P. Sakmar, A. Kuliopulos, and S.W. Hunt 3rd Insider access: pepducin symposium explores a new approach to GPCR modulation Ann. N. Y. Acad. Sci. 1180 Suppl 1 2009 E1 E12
9. Kenneth E. Carlson, T. J. M., Stephen W. Hunt (2012) Pepducins: lipopeptide allosteric modulators of GPCR signaling. Drug discovery today. Technologies 9, e1-e70.
10. S.L. Tressel, G. Koukos, B. Tchernychev, S.L. Jacques, L. Covic, and A. Kuliopulos Pharmacology, biodistribution, and efficacy of GPCR-based pepducins in disease models Methods Mol. Biol. 683 2011 259 275
11. P. Dimond, K. Carlson, M. Bouvier, C. Gerard, L. Xu, L. Covic, A. Agarwal, O.P. Ernst, J.M. Janz, T.W. Schwartz, T.J. Gardella, G. Milligan, A. Kuliopulos, T.P. Sakmar, and S.W. Hunt 3rd G protein-coupled receptor modulation with pepducins: moving closer to the clinic Ann. N. Y. Acad. Sci. 1226 2011 34 49
12. H.Y. Lee, S.D. Kim, J.W. Shim, H.J. Kim, J.Y. Kwon, J.M. Kim, S.H. Baek, J.S. Park, and Y.S. Bae Activation of human monocytes by a formyl peptide receptor 2-derived pepducin FEBS Lett. 584 2010 4102 4108
13. H. Forsman, J. Bylund, T.I. Oprea, A. Karlsson, F. Boulay, M.J. Rabiet, and C. Dahlgren The leukocyte chemotactic receptor FPR2, but not the closely related FPR1, is sensitive to cell-penetrating pepducins with amino acid sequences descending from the third intracellular receptor loop Biochim. Biophys. Acta 1833 2013 1914 1923
14. M. Winther, M. Gabl, T.I. Oprea, B. Jonsson, F. Boulay, J. Bylund, C. Dahlgren, and H. Forsman Antibacterial activity of pepducins, allosterical modulators of formyl peptide receptor signaling Antimicrob. Agents Chemother. 58 2014 2985 2988
15. M. Gabl, M. Winther, S.L. Skovbakke, J. Bylund, C. Dahlgren, and H. Forsman A pepducin derived from the third intracellular loop of FPR2 is a partial agonist for direct activation of this receptor in neutrophils but a full agonist for cross-talk triggered reactivation of FPR2 PLoS ONE 9 2014 e109516
16. H. Fu, J. Karlsson, L. Bjorkman, A.L. Stenfeldt, A. Karlsson, J. Bylund, and C. Dahlgren Changes in the ratio between FPR and FPRL1 triggered superoxide production in human neutrophils-a tool in analysing receptor specific events J. Immunol. Methods 331 2008 50 58
17. H. Forsman, E. Andreasson, J. Karlsson, F. Boulay, M.J. Rabiet, and C. Dahlgren Structural characterization and inhibitory profile of formyl peptide receptor 2 selective peptides descending from a PIP2-binding domain of gelsolin J. Immunol. 189 2012 629 637
18. A. Boyum, D. Lovhaug, L. Tresland, and E.M. Nordlie Separation of leucocytes: improved cell purity by fine adjustments of gradient medium density and osmolality Scand. J. Immunol. 34 1991 697 712
19. C. Dahlgren, T. Christophe, F. Boulay, P.N. Madianos, M.J. Rabiet, and A. Karlsson The synthetic chemoattractant Trp-Lys-Tyr-Met-Val-DMet activates neutrophils preferentially through the lipoxin A(4) receptor Blood 95 2000 1810 1818
20. J. Bylund, H. Bjornsdottir, M. Sundqvist, A. Karlsson, and C. Dahlgren Measurement of respiratory burst products, released or retained, during activation of professional phagocytes Methods Mol. Biol. 1124 2014 321 338
21. C. Dahlgren, and A. Karlsson Respiratory burst in human neutrophils J. Immunol. Methods 232 1999 3 14
22. H. Forsman, and C. Dahlgren Lipoxin A(4) metabolites/analogues from two commercial sources have no effects on TNF-alpha-mediated priming or activation through the neutrophil formyl peptide receptors Scand. J. Immunol. 70 2009 396 402
23. H. Forsman, K. Onnheim, E. Andreasson, and C. Dahlgren What formyl peptide receptors, if any, are triggered by compound 43 and lipoxin A4? Scand. J. Immunol. 74 2011 227 234
24. J. Karlsson, H. Fu, F. Boulay, J. Bylund, and C. Dahlgren The peptide Trp-Lys-Tyr-Met-Val-D-Met activates neutrophils through the formyl peptide receptor only when signaling through the formylpeptide receptor like 1 is blocked. A receptor switch with implications for signal transduction studies with inhibitors and receptor antagonists Biochem. Pharmacol. 71 2006 1488 1496
25. H. Forsman, M. Winther, M. Gabl, S.L. Skovbakke, F. Boulay, M.J. Rabiet, and C. Dahlgren Structural changes of the ligand and of the receptor alters the receptor preference for neutrophil activating peptides starting with a formylmethionyl group Biochim. Biophys. Acta 1853 2015 192 200
26. Y.S. Bae, H.Y. Lee, E.J. Jo, J.I. Kim, H.K. Kang, R.D. Ye, J.Y. Kwak, and S.H. Ryu Identification of peptides that antagonize formyl peptide receptor-like 1-mediated signaling J. Immunol. 173 2004 607 614
27. L. Covic, A.L. Gresser, J. Talavera, S. Swift, and A. Kuliopulos Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides Proc. Natl. Acad. Sci. U.S.A. 99 2002 643 648
28. R. Carr 3rd, Y. Du, J. Quoyer, R.A. Panettieri Jr., J.M. Janz, M. Bouvier, B.K. Kobilka, and J.L. Benovic Development and characterization of pepducins as Gs-biased allosteric agonists J. Biol. Chem. 289 2014 35668 35684
29. N.C. Kaneider, A.J. Leger, A. Agarwal, N. Nguyen, G. Perides, C. Derian, L. Covic, and A. Kuliopulos 'Role reversal' for the receptor PAR1 in sepsis-induced vascular damage Nat. Immunol. 8 2007 1303 1312
30. A.J. Jesaitis, J.R. Naemura, L.A. Sklar, C.G. Cochrane, and R.G. Painter Rapid modulation of N-formyl chemotactic peptide receptors on the surface of human granulocytes: formation of high-affinity ligand-receptor complexes in transient association with cytoskeleton J. Cell Biol. 98 1984 1378 1387
31. L.A. Sklar, D.A. Finney, Z.G. Oades, A.J. Jesaitis, R.G. Painter, and C.G. Cochrane The dynamics of ligand-receptor interactions. Real-time analyses of association, dissociation, and internalization of an N-formyl peptide and its receptors on the human neutrophil J. Biol. Chem. 259 1984 5661 5669
32. M.J. Lohse Dimerization in GPCR mobility and signaling Curr. Opin. Pharmacol. 10 2010 53 58
33. J.M. Gripentrog, K.P. Kantele, A.J. Jesaitis, and H.M. Miettinen Experimental evidence for lack of homodimerization of the G protein-coupled human N-formyl peptide receptor J. Immunol. 171 2003 3187 3193
34. R.S. Kasai, K.G. Suzuki, E.R. Prossnitz, I. Koyama-Honda, C. Nakada, T.K. Fujiwara, and A. Kusumi Full characterization of GPCR monomer-dimer dynamic equilibrium by single molecule imaging J. Cell Biol. 192 2011 463 480
35. S.N. Cooray, T. Gobbetti, T. Montero-Melendez, S. McArthur, D. Thompson, A.J. Clark, R.J. Flower, and M. Perretti Ligand-specific conformational change of the G-protein-coupled receptor ALX/FPR2 determines proresolving functional responses Proc. Natl. Acad. Sci. U.S.A. 110 2013 18232 18237